Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2/2012

01-04-2012

Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults

Authors: Yinon Shapira, Bat-Sheva PoratKatz, Boris Gilburd, Ori Barzilai, Maya Ram, Miri Blank, Staffan Lindeberg, Johan Frostegård, Juan-Manuel Anaya, Nicola Bizzaro, Luis J. Jara, Jan Damoiseaux, Yehuda Shoenfeld, Nancy Agmon Levin

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2012

Login to get access

Abstract

Much is known about the geoepidemiology of defined autoimmune diseases (AD); however, there is currently limited data regarding the prevalence of autoantibodies among healthy populations of different geographical areas. The aim of this study was to evaluate a large profile of autoantibodies in healthy adults from distinct global regions as well as the prevalence of anti-infectious agents antibodies in those regions. Sera samples from 557 healthy donors were obtained at six centers located in different countries (i.e., Italy, Netherlands, Israel, Mexico, Columbia, Papua New Guinea (Kitavans)). Sera were tested for the presence of antinuclear antibodies (ANA) and autoantibodies associated with thrombophilia, vasculitis, and gastrointestinal (GI) disease. Sera samples were also screened for antibodies against infectious agents (i.e., EBV, CMV, HBV, Helicobacter pylori, Treponema pallidum, and Toxoplasma gondii). Tests were performed using the BioPlex 2200 or ELISA kits (Bio-Rad Laboratories, USA). We found a significant gradient of ANA positivity among the groups: 45% of Columbians, 38% of Kitavans, 26% of Mexicans, 12% of Italians, 12% of Dutch, and 11% of Israelis were ANA positive. Geographical differences were also observed regarding the prevalence of specific autoantibodies, namely ANA: anti-dsDNA, chromatin, SmRNP, Ro/SSA, La/SSB, Scl70; GI associated: antigliadin; and thrombophilia-associated: anti-β2GP1 and prothrombin. Additionally, significant differences were observed regarding serological markers of all infectious agents screened. The observed variance between healthy ethno-geographical distinct populations in prevalence of autoantibodies may represent different genetic or environmental (e.g., prior exposure to infection) influences. Thus may illuminate possible causes of geoepidemiological differences in AD.
Literature
1.
Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y (2008) The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases—2008. Isr Med Assoc J 10(1):13–19PubMed
2.
Harel M, Shoenfeld Y (2006) Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 1069:322–345PubMedCrossRef
3.
Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266PubMedCrossRef
4.
5.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533PubMedCrossRef
6.
Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50(2):380–386PubMedCrossRef
7.
Taplin CE, Barker JM (2008) Natural evolution, prediction, and prevention of type 1 diabetes in youth. Endocr Res 33(1–2):17–33PubMedCrossRef
8.
LaGasse JM, Brantley MS, Leech NJ, Rowe RE, Monks S, Palmer JP et al (2002) Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diab Care 25(3):505–511CrossRef
9.
Rewers M, Gottlieb P (2009) Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diab Care 32(10):1769–1782CrossRef
10.
James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR et al (2007) Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16(6):401–409PubMedCrossRef
11.
Deane KD, Norris JM, Holers VM (2010) Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am 36(2):213–241PubMedCrossRef
12.
Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 38(2–3):169–177PubMedCrossRef
13.
Barzilai O, Ram M, Shoenfeld Y (2007) Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol 19:636–643PubMedCrossRef
14.
Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30:409–414PubMedCrossRef
15.
Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6(8):468–476PubMedCrossRef
16.
Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34(3):J168–J177PubMedCrossRef
17.
Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31(4):325–330PubMedCrossRef
18.
Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMedCrossRef
19.
Berkun Y, Padeh S (2010) Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 9:A319–A324PubMedCrossRef
20.
Bhat A, Naguwa S, Cheema G, Gershwin ME (2010) The epidemiology of transverse myelitis. Autoimmun Rev 9:A395–A399PubMedCrossRef
21.
Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9:A299–A304PubMedCrossRef
22.
Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287–J299PubMedCrossRef
23.
Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRef
24.
Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef
25.
Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207–J219PubMedCrossRef
26.
Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–J321PubMedCrossRef
27.
Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedCrossRef
28.
Chang C, Gershwin ME (2009) Drugs and autoimmunity—a contemporary review and mechanistic approach. J Autoimmun 34:J266–J275PubMedCrossRef
29.
Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–J286PubMedCrossRef
30.
Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293–A298PubMedCrossRef
31.
Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9:A342–A349PubMedCrossRef
32.
Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325–A329PubMedCrossRef
33.
Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 34:J307–J313PubMedCrossRef
34.
Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178–J206PubMedCrossRef
35.
36.
Lambert JF, Nydegger UE (2010) Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 9:A350–A354PubMedCrossRef
37.
Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400–A405PubMedCrossRef
38.
Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372–A378PubMedCrossRef
39.
Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251–A258PubMedCrossRef
40.
Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247–J257PubMedCrossRef
41.
Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 9:A305–A310PubMedCrossRef
42.
43.
Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379–A382PubMedCrossRef
44.
Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9:A387–A394PubMedCrossRef
45.
Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226–J233PubMedCrossRef
46.
Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:A330–A334PubMedCrossRef
47.
48.
Round JL, O'Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRef
49.
Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341PubMedCrossRef
50.
51.
52.
Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267–A270PubMedCrossRef
53.
54.
Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–A292PubMedCrossRef
55.
56.
Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163–J167PubMedCrossRef
57.
Zeki AA, Schivo M, Chan AL, Hardin KA, Kenyon NJ, Albertson TE, Rosenquist GL et al (2010) Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 34:J327–J338PubMedCrossRef
58.
Klutts JS, Liao RS, Dunne WM Jr, Gronowski AM (2004) Evaluation of a multiplexed bead assay for assessment of Epstein–Barr virus immunologic status. J Clin Microbiol 42:4996–5000PubMedCrossRef
59.
Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G et al (2005) Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann NY Acad Sci 1050:380–388PubMedCrossRef
60.
Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y (2007) Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann NY Acad Sci 1108:567–577PubMedCrossRef
61.
Ram M, Anaya JM, Barzilai O, Izhaky D, Porat Katz BS, Blank M, Shoenfeld Y (2008) The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 7:621–625PubMedCrossRef
62.
Piura B, Tauber E, Sarov B, Naggan L, Shoenfeld Y (1988) Antinuclear autoantibodies in sera of healthy pregnant women and their offspring. Am J Reprod Immunol Microbiol 18(4):116–119PubMed
63.
Yadin O, Sarov B, Naggan L, Slor H, Shoenfeld Y (1989) Natural autoantibodies in the serum of healthy women—a five-year follow-up. Clin Exp Immunol 75(3):402–406PubMed
64.
Solomon DH, Kavanaugh AJ, Schur PH, College A, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47(4):434–444PubMedCrossRef
65.
Desplat-Jego S, Bardin N, Larida B, Sanmarco M (2007) Evaluation of the BioPlex 2200 ANA screen for the detection of antinuclear antibodies and comparison with conventional methods. Ann NY Acad Sci 1109:245–255PubMedCrossRef
66.
Rose NR, Mackay IR (2000) Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol Life Sci 57:542–551PubMedCrossRef
67.
Blank M, Barzilai O, Shoenfeld Y (2007) Molecular mimicry and immunity. Clin Rev Allergy Immunol 32:111–118PubMedCrossRef
68.
Agmon-Levin N, Blank M, Paz Z, Shoenfeld Y (2009) Molecular mimicry in systemic lupus erythematosus. Lupus 18:1181–1185PubMedCrossRef
69.
Shoenfeld Y, Wilner Y, Coates AR, Rauch J, Lavie G, Pinkhas J (1986) Infection and autoimmunity: monoclonal anti-tuberculosis antibodies react with DNA and monoclonal anti-DNA autoantibodies bind to mycobacterial derived glycolipids. Clin Exp Immunol 66:255–261PubMed
70.
Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases—2008. Isr Med Assoc J 10(1):8–12PubMed
71.
Agmon-Levin N, Ram M, Barzilai O, Porat-Katz BS, Parikman R, Selmi C et al (2009) Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 32:261–266PubMedCrossRef
72.
Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B et al (2009) Infectious antibodies in systemic lupus erythematosus patients. Lupus 18(13):1129–1135PubMedCrossRef
73.
Peterson LK, Fujinami RS (2007) Chapter 3: molecular mimicry. In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) Autoantibodies, 2nd edn. Elsevier, Oxford
74.
Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I et al (2007) Autoantibodies in nonautoimmune individuals during infections. Ann NY Acad Sci 1108:584–593PubMedCrossRef
75.
Lidar M, Lipschitz N, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Pagnoux C et al (2009) Infectious serologies and autoantibodies in Wegener's granulomatosis and other vasculitides: novel associations disclosed using the Rad BioPlex 2200. Ann NY Acad Sci 1173:649–657PubMedCrossRef
76.
Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N, Tonutti E et al (2009) Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann NY Acad Sci 1173:640–648PubMedCrossRef
77.
Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, Arango A et al (2009) Anti-infectious antibodies and autoimmune-associated autoantibodies in patients with type I diabetes mellitus and their close family members. Ann NY Acad Sci 1173:633–639PubMedCrossRef
78.
Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, Maya R et al (2009) The role of infections in the immunopathogensis of systemic sclerosis—evidence from serological studies. Ann NY Acad Sci 1173:627–632PubMedCrossRef
79.
Meron MK, Amital H, Shepshelovich D, Barzilai O, Ram M, Anaya JM, Gerli R et al (2010) Infectious aspects and the etiopathogenesis of rheumatoid arthritis. Clin Rev Allergy Immunol 38(2–3):287–291PubMedCrossRef
80.
81.
Pordeus V, Barzilai O, Sherer Y, Luiz RR, Blank M, Bizzaro N et al (2008) A latitudinal gradient study of common anti-infectious agent antibody prevalence in Italy and Colombia. Isr Med Assoc J 10(1):65–8PubMed
82.
Garner MF, Hornabrook RW, Backhouse JL (1972) Prevalence of yaws on Kar Kar Island, New Guinea. Br J Vener Dis 48(5):350–355PubMed
83.
Frostegård J, Tao W, Georgiades A, Råstam L, Lindblad U, Lindeberg S (2007) Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond) 4:7CrossRef
84.
Agmon-Levin N, Bat-sheva PK, Barzilai O, Ram M, Lindeberg S, Frostegård J, Shoenfeld Y (2009) Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. Ann NY Acad Sci 1173:675–682PubMedCrossRef
85.
Blanco DR, Champion CI, Dooley A, Cox DL, Whitelegge JP, Faull K, Lovett MA (2005) A monoclonal antibody that conveys in vitro killing and partial protection in experimental syphilis binds a phosphorylcholine surface epitope of Treponema pallidum. Infect Immun 73(5):3083–3095PubMedCrossRef
86.
Sharma A, Isenberg DA, Diamond B (2001) Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmun 16(4):479–484PubMedCrossRef
87.
Rewers M (2005) Epidemiology of celiac disease: what are the prevalence, incidence, and progression of celiac disease? Gastroenterology 128(4):S47–S51PubMedCrossRef
88.
Hoffenberg EJ, MacKenzie T, Barriga KJ, Eisenbarth GS, Bao F, Haas JE (2003) A prospective study of the incidence of childhood celiac disease. J Pediatr 143(3):308–314PubMedCrossRef
89.
Plot L, Amital H, Barzilai O, Ram M, Nicola B, Shoenfeld Y (2009) Infections may have a protective role in the etiopathogenesis of celiac disease. Ann NY Acad Sci 1173:670–674PubMedCrossRef
90.
Uthman I, Khamashta M (2005) Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis 64(12):1671–1676PubMedCrossRef
91.
Mchrani T, Pertri M (2009) Epidemiology of the antiphospholipid syndrome. In: Asherson RA (ed) Handbook of systemic autoimmune diseases, vol 10. Amsterdam, Elsevier
92.
93.
Asherson RA, Cervera R, Merrill JT, Erkan D (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost 34:256–266PubMedCrossRef
94.
Sène D, Piette JC, Cacoub P (2008) Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 7(4):272–277PubMedCrossRef
95.
Zinger H, Sherer Y, Goddard G, Berkun Y, Barzilai O, Agmon-Levin N et al (2009) Common infectious agents prevalence in the antiphospholipid syndrome. Lupus 18(13):1149–1153PubMedCrossRef
Metadata
Title
Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults
Authors
Yinon Shapira
Bat-Sheva PoratKatz
Boris Gilburd
Ori Barzilai
Maya Ram
Miri Blank
Staffan Lindeberg
Johan Frostegård
Juan-Manuel Anaya
Nicola Bizzaro
Luis J. Jara
Jan Damoiseaux
Yehuda Shoenfeld
Nancy Agmon Levin
Publication date
01-04-2012
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2012
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-010-8241-z

Other articles of this Issue 2/2012

Clinical Reviews in Allergy & Immunology 2/2012 Go to the issue

ReviewPaper

Cutting Edge Issues in Rheumatic Fever

ReviewPaper

Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination

ReviewPaper

Autoimmunity and Environment: Am I at risk?

ReviewPaper

Cutting-Edge Issues in Autoimmune Orchitis

ReviewPaper

The Future of Autoimmunity

ReviewPaper

Hydroxychloroquine: From Malaria to Autoimmunity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits